Sars-cov-2 vaccines
US-2024408193-A1 · Dec 12, 2024 · US
Inactivated vaccine for chikungunya virus
US2022347286A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2022347286-A1 |
| Application number | US-202217851813-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 28, 2022 |
| Priority date | Jan 13, 2016 |
| Publication date | Nov 3, 2022 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure generally provides a purified inactivated chikungunya virus (CHIKV), methods for producing the purified inactivated CHIKV, immunogenic compositions and vaccines comprising the purified inactivated CHIKV and methods for the prevention and/or treatment of infection by CHIKV.
First claim
Opening claim text (preview).
1 . A method for immunizing a mammal against a CHIKV, wherein the method comprises administering to the mammal an effective amount of the a composition comprising a purified inactivated chikungunya virus (CHIKV). 2 . A method of eliciting a protective immune response in a human against a chikungunya virus (CHIKV) infection comprising administering a composition comprising an effective amount of a purified inactivated chikungunya virus. 3 . The method of claim 9 , wherein the administering is via a route selected from intramuscular injection, intradermal injection, subcutaneous injection, intravenous injection, oral, or intranasal. 4 . The method of claim 1 , wherein the mammal is a human. 5 . The method of claim 2 , wherein the mammal is a human. 6 . The method of claim 2 , wherein the administering is via a route selected from intramuscular injection, intradermal injection, subcutaneous injection, intravenous injection, oral, or intranasal. 7 . The method of claim 1 , wherein the effective amount confers an antibody tier sufficient for broad-based sero-protection against all strains of purified inactivated chikungunya virus (CHIKV). 8 . The method of claim 2 , wherein the effective amount confers an antibody tier sufficient for broad-based sero-protection against all strains of purified inactivated chikungunya virus (CHIKV). 9 . The method of claim 1 , wherein the effective amount is about between about 56 and 1,400 ng purified inactivated chikungunya virus (CHIKV) per dose. 10 . The method of claim 2 , wherein the effective amount is about between about 56 and 1,400 ng purified inactivated chikungunya virus (CHIKV) per dose. 11 . The method of claim 1 , wherein the purified inactivated chikungunya virus (CHIKV) is the strain AF15561, La Reunion (LR) strain, or strain 181/clone 25 strain. 12 . The method of claim 2 , wherein the purified inactivated chikungunya virus (CHIKV) is the strain AF15561, La Reunion (LR) strain, or strain 181/clone 25 strain. 13 . The method of claim 1 , wherein the purified inactivated chikungunya virus (CHIKV) is inactivated by formalin or beta-propriolactone (PBL) treatment. 14 . The method of claim 2 , wherein the purified inactivated chikungunya virus (CHIKV) is inactivated by formalin or beta-propriolactone (PBL) treatment. 15 . The method of claim 1 , wherein the composition further comprises an adjuvant. 16 . The method of claim 2 , wherein the composition further comprises an adjuvant.
Assignees
Inventors
Classifications
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
by chemical treatment · CPC title
inactivated (killed) · CPC title
by serial passage · CPC title
- A61K39/12Primary
Viral antigens · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2022347286A1 cover?
- The disclosure generally provides a purified inactivated chikungunya virus (CHIKV), methods for producing the purified inactivated CHIKV, immunogenic compositions and vaccines comprising the purified inactivated CHIKV and methods for the prevention and/or treatment of infection by CHIKV.
- Who is the assignee on this patent?
- Us Gov Sec Army
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Nov 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).